Study tests if cannabis Self-Medication theory holds up in schizophrenia
NCT ID NCT01964404
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether cannabis or a similar drug (dronabinol) can improve brain reward function in people with schizophrenia who also use cannabis. 263 participants took part to see if these substances help regulate brain circuits linked to motivation and pleasure. The goal was to understand if cannabis acts as a form of self-medication for these patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
263 people
The number who actually took part.
- Start date
-
Jul 2014
- Finished
-
Sep 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Groups 1-3 Participants with schizophrenia and a cannabis use disorder 1. Ages 18 - 55 years 2. Diagnosis of schizophrenia 3. Diagnosis of cannabis abuse or dependence 4. Use of cannabis within the month prior to screening 5. Willing to remain abstinent for the 14 days before the baseline assessments and throughout the two scans. 6. Psychiatrically stable 7. Treated with a stable dose of an antipsychotic medication (except clozapine) for the past month 8. Not seeking treatment for their cannabis use disorder. Group 4 - Control participants with schizophrenia 1. Ages 18 - 55 years 2. Diagnosis of schizophrenia 3. Willing to remain abstinent as described above 4. Psychiatrically stable 5. Treated with a stable dose of an antipsychotic medication (except clozapine) for the past month Groups 5-7 - Control participants with cannabis use disorder 1. Ages 18 - 55 years 2. Diagnosis of cannabis abuse or dependence 3. Use of cannabis within the month prior to screening 4. Willing to remain abstinent as described above 5. Not seeking treatment for their cannabis use disorder. Group 8 - Healthy control participants 1. Ages 18 - 55 years 2. Willing to remain abstinent as described above Exclusion criteria: Groups 1-3 with schizophrenia and a cannabis use disorder 1. Positive symptoms of psychosis (\> 4 \[moderate\]) on any item of the Positive and Negative Syndrome Scale psychosis subscale (once abstinent) except for the hallucination item. We will exclude for a rating \> 5 for this item. 2. Cocaine/stimulant use disorder 3. Pharmacological treatment for addiction 4. Mental retardation 5. History of head injury 6. Metal objects within the body that would contraindicate and MRI 7. Pregnancy or currently nursing 8. Uncontrolled medical condition 9. Taking clozapine 10. Any condition that would contraindicate use of cannabis or dronabinol. 11. History of a seizure disorder Group 4 - Control participants with schizophrenia 1. Positive symptoms of psychosis (\> 4 \[moderate\]) on any item of the Positive and Negative Syndrome Scale psychosis subscale (once abstinent) except for the hallucination item. We will exclude for a rating \> 5 for this item. 2. Any history of a substance use disorder other than nicotine 3. Pharmacological treatment for addiction 4. Mental retardation 5. History of head injury 6. Metal objects within the body that would contraindicate and MRI 7. Pregnancy or currently nursing 8. Uncontrolled medical condition 9. Taking clozapine Groups 5-7 - Control participants with cannabis use disorder 1. Axis I psychiatric diagnosis other than a cannabis use disorder 2. Taking any psychotropic medication 3. Pharmacological treatment for addiction 4. Mental retardation 5. History of head injury 6. Metal objects within the body that would contraindicate and MRI 7. Pregnancy or currently nursing 8. Uncontrolled medical condition 9. History of a seizure disorder Group 8 - Healthy control participants 1. Any Axis I psychiatric diagnosis 2. Taking any psychotropic medication 3. Pharmacological treatment for addiction 4. Mental retardation 5. History of head injury 6. Metal objects within the body that would contraindicate and MRI 7. Pregnancy or currently nursing 8. Uncontrolled medical condition 9. Current tobacco smokers
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cannabis use disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
-
University of Vermont
Burlington, Vermont, 05401, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a website help people cut back on cannabis?
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug